# US 2022/0033823 A1 · Recombinant virus products and methods for inhibiting expression of dystrophia myotonica protein kinase and/or interfering with a trinucleotide repeat expansion in the 3' untranslated region of the dmpk gene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033823 A1
- Document ID: US20220033823A1
- Status: Published application
- Kind: A1
- Application number: 17/269,741
- Filed: 2019-08-22
- Published: 2022-02-03
- Earliest claimed: 2018-08-22
- Assignees: Research Institute At Nationwide Children's Hospital
- Applicants: Research Institute At Nationwide Children's Hospital
- Inventors: Nicolas Sebastien Wein; Scott Quenton Harper; Kelly Reed Clark
- Web page: https://patentgrep.com/patent/US20220033823A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/86: Viral vectors
- C12N 2320/33: Alteration of splicing
- C12N 2330/51: Specially adapted vectors
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to RNA interference-based methods for inhibiting the expression of the dystrophia myotonia protein kinase (DMPK) gene. Recombinant adeno-associated viruses of the disclosure deliver DNAs encoding inhibitory RNAs that knock down the expression of DMPK or interfere with the expression of the CTG repeat associated with myotonic dystrophy type-1 (DM1). The methods have application in the treatment of myotonic dystrophies, including DM1, and other disorders associated with aberrant DMPK expression.

## Claims

### Claim 1

A nucleic acid comprising
a) a dystrophia myotonia protein kinase (DMPK) RNA-encoding nucleotide sequence comprising at least about 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the sequence set forth in any one of SEQ ID NOs: 3-19;
b) a DMPK U6shRNA-encoding nucleotide sequence comprising at least about 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the sequence set forth in any one of SEQ ID NOs: 20-24;
c) a DMPK U7snRNA-encoding nucleotide sequence comprising at least about 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the sequence set forth in any one of SEQ ID NOs: 25-36;
d) a DMPK RNA-encoding nucleotide sequence comprising at least about 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the sequence set forth in any one of SEQ ID NOs: 37-48;
e) a DMPK RNA-encoding nucleotide sequence that binds to the sequence set forth in any one of SEQ ID NOs: 37-48;
f) a DMPK RNA reverse complementary sequence comprising at least about 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the sequence set forth in any one of SEQ ID NOs: 49-60;
g) a DMPK U7RNA-encoding reverse complementary sequence comprising at least about 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the sequence set forth in any one of SEQ ID NOs: 61-72; and/or
h) a combination of any one or more of (a), (b), (c), (d), (e), (f), and/or (g).

### Claim 2 (depends on 1)

A viral vector comprising the nucleic acid of claim 1.

### Claim 3 (depends on 2)

The viral vector of claim 2, wherein the viral vector is an adeno-associated virus (AAV), adenovirus, lentivirus, retrovirus, poxvirus, baculovirus, herpes simplex virus, vaccinia virus, or a synthetic virus.

### Claim 4 (depends on 3)

The viral vector of claim 3, wherein the viral vector is an AAV.

### Claim 5 (depends on 4)

The viral vector of claim 4, wherein the AAV lacks rep and cap genes.

### Claim 6 (depends on 4)

The viral vector of claim 4, wherein the AAV is a recombinant AAV (rAAV) or a self-complementary recombinant AAV (scAAV).

### Claim 7 (depends on 4)

The viral vector of claim 4, wherein the AAV has a capsid serotype selected from the group consisting of: AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, AAV-13, AAV-anc80, and AAV rh.74.

### Claim 8 (depends on 4)

The viral vector of claim 4, wherein the AAV has a capsid serotype of AAV-9.

### Claim 9 (depends on 4)

The viral vector of claim 4, wherein the AAV is a pseudotyped AAV.

### Claim 10 (depends on 9)

The viral vector of claim 9, wherein the AAV is AAV2/8 or AAV2/9.

### Claim 11 (depends on 4)

A composition comprising the viral vector of claim 4 and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 4)

A method of inhibiting and/or interfering with expression of a dystrophia myotonica protein kinase (DMPK) gene or interfering with the CUG triplet repeat expansion (CTGexp) in the 3′ untranslated region of the DMPK gene in a cell comprising contacting the cell with the viral vector of claim 4.

### Claim 13 (depends on 4)

A method of treating a subject suffering from a myotonic dystrophy (DM) comprising administering to the subject an effective amount of the viral vector of claim 4.

### Claim 14 (depends on 13)

The method of claim 13, wherein the DM is DM1.

### Claim 15

A method of treating a myotonic dystrophy (DM) in a subject in need thereof comprising the step of administering an effective amount of a viral vector to the subject, wherein the genome of the viral vector comprises at least one U6shRNA and/or at least one U7snRNA polynucleotide, or a combination thereof, targeted to
a) inhibit expression of exon 5 of a dystrophia myotonia protein kinase (DMPK) gene;
b) inhibit expression of exon 8 of the DMPK gene; and/or
c) interfere with the CUG triplet repeat expansion (CTGexp) in the 3′untranslated region or untranslated exon 15 of the DMPK gene.

### Claim 16 (depends on 15)

The method of claim 15, wherein the viral vector is an AAV, adenovirus, lentivirus, retrovirus, poxvirus, baculovirus, herpes simplex virus, vaccinia virus, or a synthetic virus.

### Claim 17 (depends on 16)

The method of claim 16, wherein the viral vector is an AAV.

### Claim at position 18

18-23. (canceled)

### Claim 24 (depends on 15)

The method of claim 15, wherein the U6shRNA-encoding polynucleotide comprises a nucleotide sequence comprising at least about 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the sequence set forth in any one of SEQ ID NOs: 20-24.

### Claim 25 (depends on 15)

The method of claim 15, wherein the U7snRNA-encoding polynucleotide comprises a nucleotide sequence comprising at least about 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the sequence set forth in any one of SEQ ID NOs: 25-36 and 61-72.

### Claim 26

(canceled)

### Claim 27

A method of treating a myotonic dystrophy (DM) in a subject in need thereof comprising the step of administering an effective amount of a viral vector to the subject, wherein the genome of the viral vector comprises at least one U6shRNA polynucleotide targeted to inhibit expression of exon 5 of a dystrophia myotonia protein kinase (DMPK) gene, at least one U6shRNA polynucleotide targeted to inhibit expression of exon 8 of the DMPK gene, or at least one U6shRNA polynucleotide targeted to inhibit expression of the CUG triplet repeat expansion (CTGexp) in the 3′ untranslated region or untranslated exon 15 of the DMPK gene.

### Claim at position 23

28-35. (canceled)

### Claim 36 (depends on 27)

The method of claim 27, wherein the U6shRNA-encoding polynucleotide comprises a nucleotide sequence comprising at least about 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the sequence set forth in any one of SEQ ID NOs: 20-24.

### Claim 37

(canceled)

### Claim 38

A method of treating a myotonic dystrophy (DM) in a subject in need thereof comprising the step of administering an effective amount of a viral vector to the subject, wherein the genome of the viral vector comprises at least one U7snRNA polynucleotide targeted to inhibit expression of exon 5 of a dystrophia myotonia protein kinase (DMPK) gene, at least one U7shRNA polynucleotide targeted to inhibit expression of exon 8 of the DMPK gene, or at least one U7shRNA polynucleotide targeted to inhibit expression of the CUG triplet repeat expansion (CTGexp) in the 3′untranslated region or untranslated exon 15 of the DMPK gene.

### Claim at position 27

39-46. (canceled)

### Claim 47 (depends on 38)

The method of claim 38, wherein the U7snRNA-encoding polynucleotide comprises a nucleotide sequence comprising at least about 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the sequence set forth in any one of SEQ ID NOs: 25-36 and 61-72.

### Claim at position 29

48-49. (canceled)
